1.50 / AMA PRA Category 1 Credit(s)TM 1.50 / AAPA Category 1 CME Credits 1.50 / AANP for Nurse Practitioners 1.50 / CE for Nurses (1.50 pharmacotherapeutic contact hours) 1.50 / CE for Pharmacists (0.15 CEUs)
This educational initiative is provided by CME Outfitters.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Gout is the most common form of inflammatory arthritis in the United States.1 Hyperuricemia/gout in patients with chronic kidney disease (CKD) constitutes a significant burden for patients and society. Patients who are not managed adequately experience painful gout attacks, loss of function and productivity, and may develop long-term complications. The economic burden is also increased from patient utilization of prescription medication use, emergency room visits, and hospitalizations from gout or its serious complications.
Despite effective treatment for prevention, acute attacks, and tophi, and the availability of published treatment guidelines, there are significant gaps in treatment, patient communication, and clinical and economic outcomes for patients with hyperuricemia/gout and CKD.
Audio responses from patient interviews will be at the center of the discussion in this CME Outfitters Live and On Demand as expert faculty discuss best practices, effective patient communication, and treatment options for patients with hyperuricemia or gout and CKD.
Reference: Mandell B, Keenan R. So you think you know gout? Fresh perspectives on hyperuricemia for today’s complicated patients. Medscape Website. http://www.medscape.org/viewarticle/837667. Published January 30, 2015. Accessed October 16, 2016.
Physicians, physician assistants, nurse practitioners, pharmacists, and other healthcare professionals with an interest in gout and CKD
At the end of this CME/CE activity, participants should be able to:
Execute strategies to enhance an understanding of the association among hyperuricemia, gout, and CKD
Utilize educational resources in shared decision-making discussions with patients to promote medication adherence and optimize outcomes
Implement strategies to achieve optimal clinical and economic outcomes in patients with hyperuricemia or gout and CKD
The following learning objectives pertain only to those requesting CNE credit:
Identify strategies to enhance an understanding of the association among hyperuricemia, gout, and CKD
Describe ways to engage patients with gout and CKD in discussions of gout education and medication adherence
Assess strategies to achieve optimal clinical and economic outcomes in patients with hyperuricemia or gout and CKD
Conflict Of Interest Disclosure Policy
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Allan Gibofsky, MD, JD, MACR, FACP, FCLM Professor of Medicine, Healthcare Policy and Research Weill Medical College of Cornell University Attending Rheumatologist Hospital for Special Surgery New York, NY
Dr. Gibofsky has disclosed he serves on the speakers bureaus for AbbVie Inc.; Amgen Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and UCB, Inc. He serves as consultant for AbbVie; Amgen Inc.; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He is a stock shareholder in AbbVie Inc.; Amgen Inc.; GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Pfizer Inc.; and Regeneron Pharmaceuticals, Inc.
Robin K. Dore, MD Clinical Professor of Medicine David Geffen School of Medicine at UCLA Los Angeles, CA
Dr. Dore has disclosed she received research support from AbbVie Inc.; Amgen Inc.; Eli Lilly and Company; Pfizer Inc.; and UCB, Inc. She serves on the speakers bureaus for AbbVie Inc.; Amgen Inc.; Eli Lilly and Company; Pfizer Inc.; Sanofi-Genzyme; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. She serves as consultant for AbbVie Inc.; Amgen Inc.; Eli Lilly and Company; and Sanofi-Genzyme.
Eva Hardy, MS, RN, ANP-BC Department of General Orthopedic Surgery Presbyterian Health Services Presbyterian Rust Medical Center Rio Rancho, NM
Ms. Hardy has no disclosures to report.
Jeffrey Helfand, DO, MD (peer reviewer), has no disclosures to report.
Scott Richards, PhD, PA-C, DFAAPA (peer reviewer), has no disclosures to report.
Accredited Provider Disclosure
The CME Outfitters, LLC staff has nothing to disclose.
Planners' and Managers' Disclosures
Sharon Tordoff, CHCP, (planning committee) has no disclosures to report. Jan Perez, CHCP, (planning committee) has no disclosures to report Daniela V. DiBiase, MS, (planning committee) has no disclosures to report
AMA PRA Category 1 Credit(s)TM
CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA Category I CME credit
This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This program has been reviewed and is approved for a maximum of 1.50 hours of AAPA Category 1 CME credit by the Physician Assistant Review Panel. Approval is valid for one year from the issue date of 11/22/2016. Participants may submit the post-test at any time during that period.
CE for Nurse Practitioners
This program was planned in accordance with AANP CE Standards and Policies.
This program is approved for 1.50 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Program ID 16102399. This program was planned in accordance with AANP CE Standards and Policies. (Effective 12/9/16)
CE for Nurses
CME Outfitters, LLC, is approved by the California Board of Registered Nursing,
This program is approved for a maximum of 1.50 contact hours. Provider Number CEP 15510.
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.50 contact hours of pharmacotherapeutic contact hours.
CE for Pharmacists
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.50 contact hours (0.15 CEUs)
Universal Activity Number: 0376-0000-16-028-H01-P
Activity Type: knowledge-based
Disclosure of Unlabeled Use
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There are no fees for participating in this CME/CE activity. To receive credit, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, and (3) complete the post-test and activity evaluation form, including the certificate information section.
To obtain a certificate, participants must receive a score of 75% or better on the post-test. The post-test can be accessed at the end of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact firstname.lastname@example.org.